Cardiff Oncology Sets June ASCO Data Reveal as CRDF Stock Test Nears
Cardiff Oncology was flat on Friday. The biotech said it plans an investor webcast in June to go over new mid-stage data for onvansertib, the company’s main candidate in first-line RAS-mutated metastatic colorectal cancer. Cardiff’s key moment comes with its ASCO presentation on June 2 and the webcast the following morning, which will be the next look at the CRDF-004 trial. That trial is now front and center for the company. Shares ended at $1.78, off 0.6%. After hours, the stock was hovering around $1.79.